2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human
PAPER

1423 Epigenetic age dysregulation across GATA2- and DDX41-associated myeloid neoplasms

Vikram Dhillon, DO, MBA, Jeff Justin Aguilar, MD, MBA2, Asmita Shukla, MD3, Dakshin Padmanabhan, MD4, Sikander Chohan, MD5, Julie Boerner, PhD6, Gregory Dyson, PhD7, Suresh Kumar Balasubramanian, MD8
1 Karmanos Cancer Institute, Detroit, United States
2 Karmanos Cancer Institute, Detroit, United States
3 Karmanos Cancer Institute, Detroit, United States
4 Karmanos Cancer Institute, Detroit, United States
5 Karmanos Cancer Institute, Detroit, United States
6 Karmanos Cancer Institute, Detroit, United States
7 Karmanos Cancer Institute, Detroit, United States
8 Karmanos Cancer Institute, Detroit, United States

Background: Germline GATA2 and DDX41 variants are frequently inherited predispositions to myeloid malignancies but differ substantially in clinical penetrance, age at disease onset, and patterns of progression. DNA methylation-based epigenetic clocks quantify biological aging and are associated with clonal hematopoiesis and hematopoietic dysfunction. Whether germline predisposition causes systematic and coordinated epigenetic age acceleration (EAA) and whether this reflects constitutional risk or progression to overt myeloid neoplasia remain unclear. We characterized EAA, multi-clock dysregulation, telomere-associated methylation changes, and associated transcriptional programming in patients with GATA2- and DDX41-associated myeloid disease.

Methods: We analyzed an institutional cohort of DDX41-mutated myeloid neoplasms, public GATA2 cohorts (GSE221745, GSE280776), and healthy GEO-derived controls profiled on Illumina EPIC arrays. EAA was estimated using our KAN-Clock alongside Horvath, Hannum, and PhenoAge baselines. To resolve individual clock discordance, a composite multi-clock dysregulation metric captured global methylome deviation relative to healthy aging. Serial and paired blood-marrow specimens were organized for longitudinal analysis. Stage-specific methylome shifts were quantified using a Epigenetic Progression Axis (EPA) score. Finally, GATA2 hypermethylation signatures were integrated with donor-level pseudobulk expression profiles (GSE135194) to assess promoter methylation-expression coupling.

Results: The DDX41 cohort (n=10; median age 74.5 yrs, range 47-90; 80% male) included MDS (n=4), AML (n=3), t-MN (n=1), and MPN/myelofibrosis (n=2), predominantly with cytopenias and normal cytogenetics (90%). Co-mutations included ASXL1, CUX1, JAK2, and spliceosome genes. The GATA2 cohort included 15 unique patients (22 samples; median age 37 years, range 6-75) with MDS (n=8), AML (n=1), immunodeficiency (n=3), or asymptomatic carriage (n=3). Cytogenetic abnormalities occurred in 5/9 (56%) evaluable patients (+8, n=4; -7, n=2; complex, n=2), with recurrent STAG2, SETBP1, and CSMD1 co-mutations. EAA occurred in 70% of DDX41 samples by KAN-Clock versus 60% Horvath, 50% Hannum, and 30% PhenoAge. In GATA2 samples, EAA occurred in 82% (18/22) by KAN-Clock and Hannum versus 63.6% Horvath and 32% PhenoAge. Composite multi-clock dysregulation exceeded healthy 95th percentile in 95.5% (21/22) of GATA2 samples and the 99th percentile in 86 samples%. Loss of inter-clock coordination exceeded healthy 95th and 99th percentiles in 86% and 64% of samples, respectively. Shorter DNAmTL correlated with greater consensus EAA (p=0.0006).

Exploratory longitudinal analysis detected pre-clonal epigenetic shifts up to two years before multilineage dysplasia, secondary driver mutations, or acquired monosomy 7. In GSE221745, asymptomatic P1 had a hypermethylation index of 0.126 (controls, -0.023 to 0.035), approaching overt MDS (0.158-0.212), while stable familial carriers remained near baseline (0.005 and 0.023). In GSE280776, cross-validated EPA increased monotonically from stable carriers (mean 0) to asymptomatic disease (0.561), pre-clonal dysplasia (0.726), and MDS transformation with monosomy 7 (0.809) or trisomy 8 (1.000), robust across 12 feature-selection models. Concurrent EAA and EPA >0.5 occurred in 2/2 asymptomatic future progressors versus 0/4 stable carriers. Upon clinical transformation to monosomy 7 MDS, EPA increased by 0.082 with concurrent epigenetic acceleration (mean age increase +7.4 yrs).

Cross-platform integration with donor-level single-cell RNA-sequencing profiles (GSE135194) demonstrated significant inverse methylation-expression coupling across promoter-linked loci (p=0.007). Progression-associated hypermethylation inversely correlated with core innate and myeloid programs (ELANE, AZU1, PRTN3, NOD2, TREM1, FCER1G, GFI1, and S100A8/S100A9), consistent with repression of mature myeloid programs before cytogenetic clonal expansion.

Conclusions: Germline GATA2 and DDX41 predispositions feature profound multi-clock epigenetic dysregulation. In GATA2 carriers, pre-clonal remodeling precedes cytogenetic evolution and secondary mutations by up to two years, marking an early myeloid differentiation block. These proof-of-concept longitudinal observations suggest EPA may serve as an early biomarker tool for leukemic transformation in germline predisposition clinics. This prototype is undergoing refinement in larger cohorts.

Vikram Dhillon, DO, MBA: No relevant conflicts of interest to declare.